Veraxa Biotech AG - Post de-SPAC (VRXA) Profit After Tax (2025)
Veraxa Biotech AG - Post de-SPAC's (VRXA) quarterly Profit After Tax came in at -$33601.4 in Q4 2025.
Powered by 
Analysis
Veraxa Biotech AG - Post de-SPAC (VRXA) Profit After Tax (2025) Analysis & Trends
Veraxa Biotech AG - Post de-SPAC (VRXA) has reported Profit After Tax for 1 consecutive years, with -$33601.4 the latest figure, recorded in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 472.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Veraxa Biotech AG - Post de-SPAC | 23.88 Mn | 20.47 Mn | - | -33,601.42 |